Finding the best dose of tafenoquine to cure malaria caused by Plasmodium vivax in Southeast Asia
Optimizing the dose of tafenoquine for the radical cure of Plasmodium vivax malaria in Southeast Asia
This study is looking to find the best dose of tafenoquine, a medicine for treating malaria, especially for kids and pregnant women, to help prevent the illness from coming back and make it easier for patients to stick to their treatment.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oxford NIH-funded |
| Lab location | 1 site (Oxford, United Kingdom) |
| Project ID | NIH-10925296 on NIH RePORTER |
What this research studies
This research aims to optimize the dosage of tafenoquine, a medication used to treat malaria caused by Plasmodium vivax, which is prevalent in Southeast Asia. The study will analyze data from previous clinical trials to determine the most effective dose that can prevent relapses of malaria, particularly in vulnerable populations such as children and pregnant women. By focusing on a single-dose treatment, the research seeks to improve patient compliance and health outcomes. Participants may be involved in trials assessing different doses to find the optimal amount for effective treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Plasmodium vivax malaria, particularly children and pregnant women in Southeast Asia.
Not a fit: Patients with malaria caused by other strains or those who have contraindications to tafenoquine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective single-dose treatment for malaria, significantly reducing the incidence of relapses and improving health outcomes for patients.
How similar studies have performed: Previous studies have shown that optimizing drug dosages can significantly improve treatment outcomes, suggesting that this approach may yield beneficial results.
Where this research is happening
Oxford, United Kingdom
- University of Oxford — Oxford, United Kingdom (Active)
Researchers
- Principal investigator: Chu, Cindy S — University of Oxford
- Study coordinator: Chu, Cindy S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.